Literature DB >> 22671930

MicroRNAs in the pathobiology of multiple myeloma.

Marta Lionetti1, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone, Antonino Neri.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3'untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer diagnosis, prognosis and response to therapy. So far, limited but important evidence of miRNA impaired expression has been reported in multiple myeloma (MM), suggesting implications in the pathogenesis and biology of the disease. In this review, we present a general overview of the role of miRNAs in B-cell development and associated malignancies, focusing on those most extensively characterized. We fully describe seminal studies on miRNA expression in MM, highlighting the correlations of their deregulation with pathogenesis and with distinct molecular subgroups, as well as their role in prognostic stratification. The data obtained in MM, supported by the consolidated role of miRNAs in cancer and their potential effectiveness in therapy, all provide a solid rationale for the more accurate characterization of their deregulation and the development of effective means of selectively delivering miRNAs and anti-miRNAs to myeloma cells in therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22671930     DOI: 10.2174/156800912802429274

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  18 in total

1.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

Review 2.  MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Authors:  Luna Soley; Carolyne Falank; Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

3.  MiR-19a targets suppressor of cytokine signaling 1 to modulate the progression of neuropathic pain.

Authors:  Conghui Wang; Qi Jiang; Min Wang; Dong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authors:  Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 5.  MicroRNAs in multiple myeloma and related bone disease.

Authors:  Marco Rossi; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Ann Transl Med       Date:  2015-12

6.  In silico analysis of pathways affected by differentially expressed microRNA in adrenocortical tumors.

Authors:  A Zsippai; P M Szabó; D R Szabó; Z Nagy; A Patócs; K Rácz; P Igaz
Journal:  J Endocrinol Invest       Date:  2013-07-01       Impact factor: 4.256

7.  MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4.

Authors:  Chen-Yu Wang; Long Hua; Juan Sun; Kun-Hou Yao; Jiang-Tao Chen; Jun-Jie Zhang; Jun-Hong Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.

Authors:  D Ronchetti; K Todoerti; G Tuana; L Agnelli; L Mosca; M Lionetti; S Fabris; P Colapietro; M Miozzo; M Ferrarini; P Tassone; A Neri
Journal:  Blood Cancer J       Date:  2012-11-23       Impact factor: 11.037

9.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.

Authors:  N Amodio; M T Di Martino; U Foresta; E Leone; M Lionetti; M Leotta; A M Gullà; M R Pitari; F Conforti; M Rossi; V Agosti; M Fulciniti; G Misso; F Morabito; M Ferrarini; A Neri; M Caraglia; N C Munshi; K C Anderson; P Tagliaferri; P Tassone
Journal:  Cell Death Dis       Date:  2012-11-29       Impact factor: 8.469

10.  In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.

Authors:  Maria Teresa Di Martino; Annamaria Gullà; Maria Eugenia Gallo Cantafio; Marta Lionetti; Emanuela Leone; Nicola Amodio; Pietro Hiram Guzzi; Umberto Foresta; Francesco Conforti; Mario Cannataro; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.